Arkolith/Insider Trading/VIR/Form 4

Eisner Mark

EVP and Chief Medical OfficerVir Biotechnology, Inc. (VIR) · full profile →Form 4 · filed Feb 26, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$34K
Net Open-Market Flow
-$34K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 25, 2026Sell(S)2K$9.82$19K154K
Feb 24, 2026Sell(S)2K$9.53$15K156K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-012394) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML